PT3191139T - Terapia do gene rpgr para retinite pigmentosa - Google Patents

Terapia do gene rpgr para retinite pigmentosa

Info

Publication number
PT3191139T
PT3191139T PT158253831T PT15825383T PT3191139T PT 3191139 T PT3191139 T PT 3191139T PT 158253831 T PT158253831 T PT 158253831T PT 15825383 T PT15825383 T PT 15825383T PT 3191139 T PT3191139 T PT 3191139T
Authority
PT
Portugal
Prior art keywords
gene therapy
retinitis pigmentosa
rpgr gene
rpgr
pigmentosa
Prior art date
Application number
PT158253831T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Massachusetts Eye & Ear Infirmary
Ucl Business Ltd
The Government Of The Us Secretary Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye & Ear Infirmary, Ucl Business Ltd, The Government Of The Us Secretary Department Of Health And Human Services filed Critical Massachusetts Eye & Ear Infirmary
Publication of PT3191139T publication Critical patent/PT3191139T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
PT158253831T 2014-07-24 2015-07-17 Terapia do gene rpgr para retinite pigmentosa PT3191139T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462028638P 2014-07-24 2014-07-24

Publications (1)

Publication Number Publication Date
PT3191139T true PT3191139T (pt) 2020-11-05

Family

ID=55163577

Family Applications (2)

Application Number Title Priority Date Filing Date
PT158253831T PT3191139T (pt) 2014-07-24 2015-07-17 Terapia do gene rpgr para retinite pigmentosa
PT201992088T PT3821912T (pt) 2014-07-24 2015-07-17 Terapia do gene rpgr para retinite pigmentosa

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT201992088T PT3821912T (pt) 2014-07-24 2015-07-17 Terapia do gene rpgr para retinite pigmentosa

Country Status (18)

Country Link
US (2) US10314924B2 (https=)
EP (2) EP3821912B1 (https=)
JP (3) JP6654760B2 (https=)
CN (1) CN107206105A (https=)
CA (1) CA2991750C (https=)
CY (1) CY1123793T1 (https=)
DK (2) DK3821912T3 (https=)
ES (2) ES2987090T3 (https=)
FI (1) FI3821912T3 (https=)
HR (2) HRP20202023T1 (https=)
HU (2) HUE068183T2 (https=)
LT (2) LT3821912T (https=)
PL (2) PL3821912T3 (https=)
PT (2) PT3191139T (https=)
RS (2) RS65909B1 (https=)
SI (2) SI3191139T1 (https=)
SM (2) SMT202000715T1 (https=)
WO (1) WO2016014353A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE068183T2 (hu) * 2014-07-24 2024-12-28 Massachusetts Eye & Ear Infirmary RPGR génterápia a retinitis pigmentosa terápiájára
WO2016098078A2 (en) * 2014-12-19 2016-06-23 Novartis Ag Dimerization switches and uses thereof
EP3268481B1 (en) 2015-03-11 2020-05-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Rpgr vectors for treating x-linked retinitis pigmentosa
GB201516066D0 (en) 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
GB201704192D0 (en) 2017-03-16 2017-05-03 Nightstarx Ltd Treatment of Retinitis Pigmentosa
CN111867635A (zh) * 2017-10-20 2020-10-30 法国国家卫生及研究医学协会 包括视网膜下递送治疗有效量的重组aav9衍生载体的在对象的视锥细胞光感受器中表达目的多核苷酸的方法
KR102704296B1 (ko) * 2017-11-15 2024-09-05 더 리젠츠 오브 더 유니버시티 오브 미시간 Rdh12 암호화 영역을 포함하는 바이러스 벡터 및 망막 이영양증을 치료하는 방법
EP4117644A4 (en) 2020-03-11 2024-08-14 Massachusetts Eye and Ear Infirmary GENE THERAPY FOR NMNAT1-ASSOCIATED RETINAL DEGENERATION
CN120350069A (zh) * 2024-01-12 2025-07-22 北京中因科技有限公司 视网膜色素变性动物模型及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
ES2096750T3 (es) 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
AU2044901A (en) * 1999-11-24 2001-06-04 Cornell Research Foundation Inc. Inherited retinal diseases at the canine rp3 locus: linkage, marker- and mutation-based tests
GB0008801D0 (en) * 2000-04-10 2000-05-31 Medical Res Council Sequences
CN102925445A (zh) * 2011-08-08 2013-02-13 刘军 一种获得rpgr 基因新的转录剪切形式的方法
EP2872183B1 (en) * 2012-07-11 2018-09-26 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration
GB201412011D0 (en) * 2014-07-04 2014-08-20 Ucl Business Plc Treatments
HUE068183T2 (hu) * 2014-07-24 2024-12-28 Massachusetts Eye & Ear Infirmary RPGR génterápia a retinitis pigmentosa terápiájára

Also Published As

Publication number Publication date
EP3821912A1 (en) 2021-05-19
CA2991750A1 (en) 2016-01-28
DK3191139T3 (da) 2020-11-16
US11045558B2 (en) 2021-06-29
EP3821912B1 (en) 2024-06-12
RS65909B1 (sr) 2024-10-31
ES2834402T3 (es) 2021-06-17
CA2991750C (en) 2023-02-14
JP6966532B2 (ja) 2021-11-17
LT3191139T (lt) 2021-01-25
HRP20241154T1 (hr) 2024-11-22
EP3191139A1 (en) 2017-07-19
SI3191139T1 (sl) 2021-03-31
US20170216454A1 (en) 2017-08-03
ES2987090T3 (es) 2024-11-13
FI3821912T3 (fi) 2024-08-05
JP2017523239A (ja) 2017-08-17
HUE052781T2 (hu) 2021-05-28
JP2022009333A (ja) 2022-01-14
JP6654760B2 (ja) 2020-02-26
EP3191139B1 (en) 2020-10-07
CN107206105A (zh) 2017-09-26
US10314924B2 (en) 2019-06-11
DK3821912T3 (da) 2024-08-05
WO2016014353A1 (en) 2016-01-28
SMT202000715T1 (it) 2021-01-05
EP3191139A4 (en) 2018-01-10
LT3821912T (lt) 2024-09-25
PL3821912T3 (pl) 2024-10-28
HRP20202023T1 (hr) 2021-03-05
JP7198329B2 (ja) 2022-12-28
PL3191139T3 (pl) 2021-07-05
PT3821912T (pt) 2024-08-01
SMT202400309T1 (it) 2024-11-15
CY1123793T1 (el) 2022-05-27
RS61307B1 (sr) 2021-02-26
US20200215203A1 (en) 2020-07-09
JP2020073536A (ja) 2020-05-14
SI3821912T1 (sl) 2024-10-30
HUE068183T2 (hu) 2024-12-28

Similar Documents

Publication Publication Date Title
IL275918B (en) Gene therapy for retinitis pigmentosa
ZA201802462B (en) Gene therapy
GB201420139D0 (en) Factor IX gene therapy
HUE068183T2 (hu) RPGR génterápia a retinitis pigmentosa terápiájára
GB201407322D0 (en) Gene therapy
GB201706394D0 (en) Gene Therapy
GB201707212D0 (en) Gene therapy for ciliopathies
GB201701968D0 (en) Gene therapy
GB201513151D0 (en) Functional gene replacement therapy
GB201616821D0 (en) Gene therapy
GB201612104D0 (en) Gene therapy
GB201612105D0 (en) Gene therapy
GB201704634D0 (en) Gene therapy
SG10201912076UA (en) Gene therapy composition
GB201410595D0 (en) Factor IX gene therapy